Top Stocks for Robust Returns: Halozyme, Leidos, and TransUnion Upgrade

Halozyme (HALO), Leidos (LDOS), and TransUnion (TRU) are expected to see significant earnings growth in 2025. HALO's earnings are projected to jump 46.1%, while LDOS and TRU are expected to grow 9.2% and 4.1% year over year, respectively. Both LDOS and TRU have seen upward revisions in broker ratings over the past four weeks.

Investors are keeping a close eye on several companies expected to see substantial earnings growth in 2025. Among them are Halozyme Therapeutics (HALO), Leidos Holdings (LDOS), and TransUnion (TRU). Each company is poised for significant year-over-year (YoY) growth in earnings.

Halozyme Therapeutics (HALO) is projected to experience a 46.1% increase in earnings for the current fiscal year. This growth is driven by the company's strong record of positive earnings surprises and favorable analyst revisions. HALO has beaten the Zacks Consensus Estimate in each of the last four quarters, with its latest earnings report on August 5, 2025, showing EPS of $1.54 versus the consensus estimate of $1.23 [1].

Leidos Holdings (LDOS) is expected to grow its earnings by 9.2% in 2025. The company reported an EPS of $3.21 for the last quarter, surpassing expectations, and has set its FY 2025 EPS guidance between $11.150-$11.450 [2]. Several large investors have recently increased their positions in LDOS, indicating confidence in the company's future prospects.

TransUnion (TRU) is anticipated to see a 4.1% increase in earnings for the current year. While specific earnings projections for TRU were not detailed in the provided materials, the company's upward revisions in broker ratings over the past four weeks suggest positive sentiment among analysts.

Both LDOS and TRU have seen upward revisions in broker ratings over the past four weeks, indicating growing confidence among financial professionals. Leidos, in particular, has received a "Moderate Buy" consensus rating with an average target price of $179.46 [2]. TransUnion's positive sentiment is reflected in its recent earnings reports and analyst coverage.

Investors should monitor these companies closely as they approach their earnings reports for the fiscal year 2025. The projected earnings growth and positive analyst revisions suggest that these companies are well-positioned for continued success.

References:

[1] https://www.nasdaq.com/articles/halozyme-therapeutics-inc-halo-hit-52-week-high-can-run-continue

[2] https://www.marketbeat.com/instant-alerts/filing-comerica-bank-trims-stock-position-in-leidos-holdings-inc-ldos-2025-08-30/